CSF2 and COVID-19: Aberrant high GM-CSF levels have been detected in circulating lymphocyte populations, excluding NKs and B cells, from patients with COVID-19 admitted to ICU.78 Therefore, the potential of GM-CSF-blocking antibodies such as lenzilumab (LIVE-AIR study) and gimsilumab to treat COVID-19 is being evaluated by researchers and pharmaceutical companies.441